![]() ![]() "We believe this transaction provides Endo with an enhanced competitive position and critical mass in the generics market, further diversifying our business lines and product offerings and enhancing our portfolio of pain management products. healthcare environment," said Dave Holveck, president and CEO of Endo. "This acquisition marks another milestone in the transformation of Endo and accelerates our stated strategy of building a diversified healthcare company, better able to respond to the changing economics that drive the U.S. ![]() 28 that it entered into a definitive agreement to acquire Qualitest Pharmaceuticals, a leading, privately held generics company in the U.S., for approximately $1.2 billion in cash. Or GAAP diluted EPS to a range of $2.42 to $2.52.Įndo Pharmaceuticals (Nasdaq: ENDP) announced today the completion of its acquisition of Qualitest Pharmaceuticals. Endo reaffirms 2011 guidance for revenue of $2.2 billion to $2.3īillion, adjusted diluted EPS of $4.15 to $4.25. Endo increases 2010 guidance for revenue to approximately $1.7 billionĪnd increases adjusted diluted EPS to a range of $3.35 to $3.40.ĭecreases 2010 Reported or GAAP diluted EPS to a range of $1.66 to ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |